Heart transplantation and mechanical circulatory support are advanced therapies for conditions in which the heart can no longer provide adequate perfusion despite treatment of the underlying heart disease and its consequences. Heart transplantation replaces the diseased heart with a donor organ; mechanical ventricular assistance transfers part of the circulatory workload to a pump, generally leaving the native heart in place. The two strategies may be alternatives, but they may also follow one another along the same treatment pathway: temporary support can help a patient survive a critical phase, a durable device can provide support while awaiting transplantation, and, in selected patients, ventricular unloading contributes to sufficient recovery to permit removal of the device.
The common underlying condition is advanced heart failure, a syndrome defined by the combination of persistent symptoms, severe cardiac dysfunction, episodes of instability and marked functional limitation, rather than by ejection fraction alone. It may arise from ischemic heart disease, nonischemic cardiomyopathies, restrictive disorders, congenital heart disease or other structural conditions. The potentially eligible population is larger than the population actually undergoing advanced procedures: donor availability, reversibility of extracardiac damage, anatomy, frailty and the person's goals all contribute to determining the indication. The frequency of individual procedures also depends on donation systems and access to specialist centers and is not a direct measure of the prevalence of advanced heart failure.
Technological progress has changed outcomes particularly for durable mechanical support. In the MOMENTUM 3 trial, a magnetically levitated centrifugal-flow device reduced major pump-related events compared with the axial-flow comparator; extended observational follow-up documented benefits for up to five years. These findings describe a selected population and a particular device comparison: they do not demonstrate that mechanical support and transplantation are interchangeable, nor do they allow direct comparison of survival percentages obtained from different patient cohorts. Clinical decisions require an assessment of individual benefit, encompassing expected survival, the degree of independence that can be regained and the burden of subsequent care.
Irreversible myocardial loss after infarction, cardiomyocyte injury in inherited or acquired cardiomyopathies, and chronic pressure or volume overload may converge to reduce cardiac pumping reserve. Progression to the advanced stage depends on the amount of remaining functional tissue, ventricular geometry, the pulmonary circulation and other organs' ability to tolerate congestion. A correctable valvular disorder, tachycardia-induced cardiomyopathy or potentially reversible myocarditis calls for a different approach from that used for a diffusely fibrotic ventricle: any support must preserve the time needed for cause-directed therapy, without prematurely turning a possibility of recovery into a definitive indication for heart replacement.
In a dilated ventricle, increasing chamber radius and filling pressures raise wall stress. Sympathetic and renin–angiotensin–aldosterone system activation initially sustains blood pressure and perfusion but promotes vasoconstriction, sodium and water retention, fibrosis and further remodeling. Reduced energy efficiency, abnormalities in excitation–contraction coupling and disorganization of the extracellular matrix progressively diminish the effectiveness of further preload increases. The heart may maintain an acceptable resting output at the cost of high venous pressures, only to become unable to increase blood flow during minimal activity. Part of the benefit of neurohormonal treatments comes from interrupting these pathways, but hypotension and renal dysfunction may limit their administration at the most advanced stage.
Venous congestion is more than a marker of severity. Elevated renal venous pressure reduces the kidney's perfusion gradient and promotes sodium retention, while bowel edema can interfere with nutrition and drug absorption. Hepatic congestion causes cholestasis and, if prolonged, structural changes; reduced blood supply adds an ischemic component. These mechanisms explain why worsening renal function does not automatically mean irreversible nephropathy and why, conversely, only mildly elevated creatinine in someone with sarcopenia may underestimate injury. Distinguishing functional impairment from established organ disease is essential for predicting what circulatory therapy can actually reverse.
The right ventricle is one of the main determinants of treatment selection. Pulmonary venous hypertension due to left-sided failure may over time be accompanied by vasoconstriction and remodeling of the pulmonary arterial bed. The right ventricle must then generate greater pressure against a less compliant circulation until its adaptation becomes inadequate. An LVAD unloads the left ventricle and often lowers pulmonary pressures, but it increases effective venous return to the right heart and changes septal geometry. An already impaired right ventricle may consequently fail to supply the pump. Right ventricular failure after LVAD implantation results from this interaction, to which perioperative injury, arrhythmias and valvular abnormalities may contribute.
Ventricular unloading also changes myocardial work. By drawing blood from the left ventricle and returning it to the aorta, an LVAD can lower end-diastolic volume and pressure, wall tension and oxygen consumption while improving systemic perfusion. The magnitude of the effect depends on pump speed, preload and the pressure gradient between the ventricle and aorta. A centrifugal device does not guarantee a fixed output independent of the patient's condition: hypovolemia, right-sided failure, tamponade or increased afterload may reduce flow. Excessive unloading, conversely, can cause chamber collapse, suction events and septal displacement, worsening biventricular balance.
Extracorporeal venoarterial support has a different physiology. It drains venous blood, oxygenates it and returns it to the arterial system, supporting both circulation and gas exchange; in peripheral configurations, retrograde flow may increase left ventricular afterload. If the ventricle cannot eject, distension, blood stasis and pulmonary congestion may develop, making a decompression strategy necessary. Temporary assistance must therefore be selected according to the deficit requiring correction: left, right or biventricular failure, possible hypoxemia and potential for recovery. Biological replacement with an allograft instead restores a pulsatile pump but introduces new physiological conditions, including denervation and the need for permanent control of the recipient's immune response.
History-taking should reconstruct changes in functional capacity rather than merely establish the presence of dyspnea. Progressive restriction of everyday activities, the need to stop during personal hygiene, orthopnea, nighttime awakenings with breathlessness and increasing diuretic doses all indicate declining reserve. Patients may predominantly report fatigue, slowness and difficulty concentrating—findings compatible with hypoperfusion but requiring interpretation alongside anemia, sleep disorders and other comorbidities. Comparing current activity with what the person could do several months earlier reveals deterioration that an already sedentary lifestyle may conceal.
The sequence of recent events helps distinguish stably severe disease from rapidly worsening disease. Recurrent admissions for congestion, episodes of low cardiac output, inotropic requirements, appropriate implantable defibrillator shocks and increasing intolerance of disease-modifying medication are warning signs. Inotrope dependence should be recognized when dose reduction causes renewed hypoperfusion or clinical deterioration, not simply because a drug remains prescribed. An apparently improved isolated parameter during infusion does not indicate independent stabilization. Correctable precipitants, such as infection, ischemia, arrhythmias, treatment interruptions or drug interactions, must also be sought.
Digestive and nutritional disturbances may precede more obvious signs of right-sided failure. Early satiety, abdominal distension, nausea, limb edema and rapid weight fluctuations suggest congestion; loss of muscle mass and unintentional weight loss suggest longer-standing systemic involvement. Body weight must be interpreted in the context of fluid balance: resolution of edema may unmask pre-existing sarcopenia. Falls, difficulties managing medication, family support and living conditions also matter during the interview, because hemodynamic improvement does not automatically remove barriers to independence.
Physical examination begins with overall appearance, level of alertness, respiratory rate and signs of perfusion. Cold extremities, mottling, narrow pulse pressure and reduced urine output suggest inadequate cardiac output, whereas seemingly preserved arterial pressure may reflect marked vasoconstriction. Assessment of jugular venous pressure and hepatojugular reflux, cardiac and pulmonary auscultation, and examination for effusions, ascites and edema establish the distribution of congestion. Crackles may be limited despite high filling pressures in chronic heart failure; their absence does not exclude substantial hemodynamic compromise.
Combining perfusion and congestion is more useful than applying a simple severity label. A congested but adequately perfused patient may benefit from intensive optimization, whereas a patient with little congestion but hypoperfusion may have extremely limited reserve. Cardiogenic shock requires recognition of inadequate organ perfusion attributable to the heart, taking blood pressure, lactate, urine output, neurological status and the time course into account. Not all advanced heart failure represents shock, and not every episode of shock warrants durable LVAD support or transplantation: the condition may be reversible or accompanied by extracardiac damage that makes definitive treatment impracticable.
Assessment also includes the person's priorities. The same functional limitation may be experienced differently depending on age, activities, support network and willingness to undergo interventions, monitoring and possible hospital admissions. Communication must establish that the patient understands the difference between a procedure requiring lifelong immunosuppression and one involving everyday management of a controller, batteries and a driveline. Involving caregivers and rehabilitation professionals helps identify modifiable needs. Early referral to an advanced center is valuable precisely because it leaves time for nutritional support, functional recovery and care planning before urgency narrows the options.
The first goal of investigations is to confirm that the limitation truly results from heart disease and that conventional treatment options have been addressed. ECG, echocardiography, blood tests and record review allow assessment of ventricular function, valve disease, arrhythmias and renal and hepatic status. Cardiac magnetic resonance, coronary assessment, genetic testing or myocardial biopsy are indicated for specific questions, especially where they may identify a treatable cause. Advanced heart failure is not diagnosed by nonspecifically ruling out every other disease but by demonstrating severe heart disease accompanied by persistent clinical impairment despite appropriate care.
The Heart Failure Association definition, incorporated into ESC guidelines, identifies advanced heart failure through the simultaneous presence of the following features despite optimal treatment:
This definition describes a clinical syndrome and is not equivalent to the criteria for transplant listing. A patient may need advanced assessment before meeting all the elements, for example with refractory arrhythmias or rapid deterioration. Cardiopulmonary exercise testing, when it can be performed safely, measures the integrated reserve of heart, lungs and muscles. Peak oxygen consumption must be interpreted in relation to effort quality, treatment, sex, age and body composition; the ventilation–carbon dioxide production slope provides additional information when effort is submaximal. Poor performance due to osteoarthritis, obesity or respiratory disease does not, by itself, demonstrate an indication for heart replacement.
Right heart catheterization measures filling pressures, cardiac output and pulmonary vascular resistance, providing information that echocardiography cannot fully replace. High pulmonary pressure may result predominantly from backward transmission of elevated left atrial pressure or from an additional vascular component. Treating congestion and, in appropriate cases, performing a vasodilator challenge help estimate reversibility. This distinction matters for both strategies: a normal donor right ventricle may not tolerate fixed pulmonary afterload, whereas left ventricular unloading with an LVAD can reduce part of the pulmonary load over time and make transplantation feasible.
Characterizing target organs requires more than a single measurement. Renal assessment considers filtration trends, proteinuria, urinalysis and morphology; hepatic assessment considers markers of cholestasis and synthetic function, imaging and selected further tests if advanced fibrosis is suspected. Congestion can complicate some noninvasive measurements of liver stiffness. Respiratory and vascular assessment clarifies whether another disease will limit achievable benefit. In selected cases irreversible organ damage prompts consideration of combined transplantation; in others it makes the risk of any advanced intervention excessive. It is therefore essential to distinguish what improved perfusion may correct from what will persist after intervention.
Infectious disease and oncological assessment identifies active conditions, latent infections and reactivation risks, while immunological work-up measures sensitization to donor antigens. Frailty is assessed alongside nutrition, cognition and rehabilitation potential, without treating it as an immutable label. Psychosocial assessment examines adherence, understanding, dependencies and care resources, with targeted interventions for modifiable problems. For a durable device, ventricular size and geometry, right ventricular function, the aortic valve and intracardiac shunts are also important. For transplantation, blood group and immunological compatibility, body size and anticipated waiting times are relevant. The decision is multidisciplinary and is revisited when the clinical picture changes.
Advanced evaluation proceeds alongside treatment of the underlying heart disease. In heart failure with reduced ejection fraction, disease-modifying medications are continued or introduced according to indications and tolerability, while diuretics and correction of precipitating factors control congestion. Revascularization, valve treatment, resynchronization and arrhythmia interventions may change the pathway in suitable patients. A temporary fall in blood pressure or change in renal function must be interpreted in context, because both unjustified withdrawal of useful treatments and their continuation during severe hypoperfusion can be harmful. Advanced disease calls for frequent reassessment, not simply repetition of a treatment regimen that has become inadequate.
During acute instability, inotropes can sustain output and vasopressors maintain the pressure needed for perfusion. Their use must have a clearly defined goal and close reassessment: recovery, transfer, definitive intervention or palliation. Prolonged escalation of catecholamines increases metabolic demand and arrhythmic risk and cannot replace mechanical support when pump failure remains refractory. The choice among intra-aortic balloon counterpulsation, a microaxial pump, right ventricular support and extracorporeal venoarterial support depends on hemodynamic phenotype, severity, oxygenation and technical feasibility. No single device is optimal for every form of shock.
The term bridge to decision describes temporary support that allows clarification of reversibility, neurological integrity and treatment options. Bridge to recovery instead aims for native heart recovery; bridge to transplant sustains the patient until a donor organ becomes available; bridge to candidacy seeks to correct a potentially reversible obstacle, such as a component of pulmonary hypertension. Destination therapy is a durable-support strategy for patients for whom transplantation is not feasible but the device may offer meaningful benefit. These categories describe the initial intention and may change as the clinical situation evolves.
Transplantation provides biventricular replacement and may be particularly important when anatomy or physiology makes isolated LVAD support unsuitable. It nonetheless requires a compatible organ, a reasonable likelihood of surviving the wait and an extracardiac profile that allows the patient to benefit from surgery and immunosuppression. Durable assistance can be planned with less dependence on donor availability and may improve perfusion, functional capacity and nutritional status, but requires careful evaluation of right ventricular function and hemorrhagic, infectious and neurological risks. Timing of implantation is crucial: waiting until multiorgan collapse may remove an opportunity that existed earlier.
After LVAD implantation, pump speed, volume status, arterial pressure and treatment of the remaining native heart are adjusted through clinical and echocardiographic monitoring. Antithrombotic treatment is tailored to the device and clinical profile. The ARIES-HM3 trial showed that, in HeartMate 3 recipients treated with a vitamin K antagonist, omitting aspirin may reduce bleeding without worsening the composite outcome studied; this finding does not justify stopping the anticoagulant or automatically applying the same strategy to every other system. Patient education about electrical power, alarms and driveline care is an integral part of treatment because continuity of support also depends on correctly performed daily procedures.
After transplantation, management focuses on preserving graft function and balancing immunological protection against toxicity. Monitoring includes rejection surveillance, measurement of immunosuppressant concentrations, infection prevention and management of metabolic and vascular risk. Rehabilitation improves exercise capacity and independence, taking the chronotropic response of the denervated heart and pre-existing deconditioning into account. In both pathways, quality of life depends on the combination of cardiac function, muscle recovery, psychological well-being, frequency of admissions and ability to sustain treatment, not simply on an echocardiographic measurement.
Prognosis should be discussed as a range of possible outcomes. Biological age, severity at the time of the procedure, function of other organs, complications and quality of follow-up substantially modify outcomes. Device studies show that fewer thrombotic and neurological events can increase the duration of support, while transplant experience demonstrates the growing burden of chronic complications in long-term survivors. Palliative care may accompany active treatment at any stage, helping control symptoms and define priorities. When no advanced strategy offers proportionate benefit, the care pathway must retain concrete goals of comfort, continuity of care and support for the patient and family.
Complications of advanced therapies arise through different mechanisms and must be interpreted according to the phase of treatment. Perioperative complications are mainly bleeding, organ failure, infection and hemodynamic instability. After transplantation, an early decline in function may result from primary cardiac graft dysfunction, a surgical problem, high pulmonary afterload or hyperacute rejection; distinguishing these causes immediately changes treatment. The ISHLT consensus published in 2026 updated the terminology of early dysfunction, distinguishing events within 24 hours from those occurring between 24 and 72 hours and keeping conditions with an identifiable secondary cause separate.
The immune response can damage the transplanted heart through cellular infiltration and cardiomyocyte injury, or through antibodies and microvascular damage. Acute cellular rejection and antibody-mediated rejection require specific characterization and may arise before clinically evident impairment. Over the longer term, cardiac allograft vasculopathy may diffusely affect epicardial coronary arteries and the microcirculation, making a search for focal stenoses alone less reliable. Denervation may attenuate angina: surveillance cannot depend exclusively on the onset of chest pain.
Immunosuppression changes susceptibility to common and opportunistic infections, while some medications contribute to renal injury, hypertension, glucose abnormalities and dyslipidemia. Cancer risk rises through the interaction of reduced immune surveillance, oncogenic viruses and individual factors. Prevention of infections after heart transplantation includes preoperative assessment, targeted prophylaxis and surveillance, with attention to changes in risk when antirejection therapy is intensified. Chronic problems may accumulate: renal dysfunction limits medication options and increases vulnerability to infections and invasive procedures.
During mechanical support, contact between blood and artificial surfaces, shear forces and regions of altered flow affect hemostasis and red blood cell integrity. Device thrombosis may impair flow, increase pump power consumption and cause emboli or hemolysis. Not every low-flow alarm indicates thrombosis: hypovolemia, right ventricular dysfunction and circuit obstruction must be investigated. Assessment integrates alarm trends, device parameters, biomarkers and imaging; prematurely attributing the problem to a single cause can delay a decisive corrective measure.
LVAD-associated bleeding results from the interaction of antithrombotic treatment, platelet abnormalities, loss of high-molecular-weight von Willebrand factor multimers and gastrointestinal vascular lesions. Hemorrhage may require transfusion and changes in treatment that, in turn, increase thrombotic risk. The driveline permanently crosses the skin barrier and provides a potential entry route for microorganisms; a superficial infection may extend into deeper tissues or involve the system. Exit-site care and minimizing traction-related trauma are therefore preventive measures with a precise anatomical rationale.
As support continues, aortic regurgitation, arrhythmias and deterioration of right ventricular function may develop. Aortic regurgitation can create recirculation between the aorta, ventricle and pump: the flow displayed by the device then does not entirely correspond to effective perfusion. Ventricular arrhythmias sometimes tolerated because of left-sided support may nonetheless reduce right ventricular output. These interactions require integrated surveillance and reassessment of options, including transplantation when feasible. Continuity between the specialist center, community cardiology services and other clinicians helps identify early clinical changes that, when interpreted in the context of the device or transplant, can be treated before systemic deterioration occurs.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.